Akebia Therapeutics

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

By Therapeutic Area

top 1

Nephrology

1100%

R&D Momentum

40/100

Pipeline Velocity

19/100

Trial Completion Rate

88/100

Pipeline Concentration

100/100

Pipeline Freshness

95/100

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Recruiting

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis

Earlier

Mar 1, 2026TrialSAD and MAD Study of AKB-9090 in Healthy Adult Participants

Jul 24, 2025TrialTo Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Jan 1, 2025TrialStudy to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

Jan 1, 2025TrialStudy to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

Mar 27, 2024FDAVafseo — VAFSEO

Jun 18, 2021TrialStudy Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Jun 15, 2020TrialStudy in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

3 more events

May 27, 2020TrialTrial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

May 28, 2019TrialStudy to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Jan 31, 2019TrialStudy of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Vafseo4 patentsJun 26, 2027 Vafseo2 patentsMar 13, 2028 Vafseo6 patentsJun 4, 2034 Vafseo2 patentsMar 31, 2036

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Nephrology

Focal Segmental Glomerulosclerosis

Praliciguat

Nephrology

Focal Segmental Glomerulosclerosis

PraliciguatPhase 2

Regulatory

Regulatory Timeline

20241 event

FDAMar 27

Vafseo — VAFSEO

Application NDA215192 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)